Skip to content
Abierto

Special notice

Notice of Intent to Sole Source MP201 Drug Synthesis

HT9425-24-Q-0095

Defense Health Agency (Dha), Army Med Res Acq Activity. Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).

Awarded

Mitochon Pharmaceuticals, Inc.

$50,000.00 obligated so far on USAspending

Description

As published on SAM.gov.

The U.S. Army Medical Research Acquisition Activity (USAMRAA) in support of the Walter Reed Army Institute of Research (WRAIR) intends to negotiate solely (as prescribed in FAR 13.106(b)(1)(i)) with Mitochon Pharmaceuticals, 970 Cross Ln, Blue Bell, PA 19422, to provide synthesis of the prodrug of 2,4-dinitrophenol (DNP) called MP201, against ocular dysfunction caused by blast exposure, for WRAIR’s Blast Induced Neurotrauma Branch’s (BINT) study on the efficacy of the drug MP201 by data interpretation/analysis, preparation of quarterly reports, annual progress reports, manuscripts, and final project report..

The MP201 required for this study, is developed and synthesized by Mitochon Pharmaceuticals and is not available through any other source. The North American Industry Classification System (NAICS) for this requirement is 541715 and the size standard is 1000. This announcement constitutes the only notice by the government; a written solicitation will not be issued. All sources that believe they are eligible to provide these items must respond in writing.

Responses must be supported with clear and convincing evidence to clearly articulate the ability to provide the items outlined above. A request for documentation will not be considered an affirmative response. This Special Notice of Intent is not a request for competitive quotes. Information received will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government.

If no written responses are received by the date listed below, the purchase will be awarded without further remark. All questions and responses concerning this notice shall be emailed to Ms. Dawn Jennings at dawn.v.jennings.civ@health.mil. Interested concerns must identify their capability in writing to the above e-mail address or by mail to the address listed below no later than 12:00PM ET, July 26, 2024. Contracting Office Address:

US Army Medical Research Acquisition Activity, ATTN: FCMR-ACO-AA, 808 Schreider Street, Frederick, MD 21702-5014 Point of Contact: Dawn Jennings Dawn.v.jennings.civ@health.mil

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

UEI
JGJ7TELAKUY8
CAGE
7NNV1
Vendor location
Blue Bell, PA
Contract
HT942525P0014, purchase order
Obligated
$50,000.00, potential $150,000
Actions
1 between November 7, 2024 and November 7, 2024
Competition
Not Competed Under SAP, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
MP201 Drug Development/Synthesis
Match
solicitation number HT942524Q0095 equals the FPDS solicitation identifier; same awarding office HT9425 (high confidence)

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. July 11, 2024

    Special notice, originally sources sought

    Due July 26, 2024 at 12:00 PM EDT. SAM.gov, notice c9f826b4d9d6476bb38304db1a77dfa1

Points of contact